HQP Synaptozone
 

Can you briefly explain your current research project, including its main focus and objectives? 

We use iPSC-derived brain organoids to model disease pathophysiology in a three-dimensional system, overcoming limitations related to tissue access. Since brain organoids require extended maturation times, our goal is to accelerate this process using a small molecule cocktail, enabling faster integration into drug testing pipelines. Additionally, we aim to develop a drug screening platform using midbrain organoids that carry synuclein aggregates, facilitating the testing of drugs for Parkinson’s disease.

 

What initially drew you to this field of research? 
 

I've always been curious about how the human body works, which sparked my interest in biology. At the same time, I wanted to contribute to helping others, which led me to research. I had my first hands-on experience in a lab during my master’s in neuroscience at the University of Montreal, where we studied the blood-brain barrier. This experience solidified my passion for neuroscience and experimental research. Later, I joined the Neuro’s EDDU brain organoid team, where I discovered a dynamic and rapidly evolving field that continues to fascinate me.

 

What is one key takeaway or message you want people to remember from your research? 
 

Our research shows that advanced models like brain organoids can be leveraged for therapeutics and personalized medicine. By refining these models, we aim to accelerate drug discovery and develop targeted treatments for neurological diseases.


           Check Out More About The iPSC& Organoid Core Here!